Annual EBITDA
-$94.31 M
+$143.20 M+60.29%
December 31, 2023
Summary
- As of February 7, 2025, MCRB annual EBITDA is -$94.31 million, with the most recent change of +$143.20 million (+60.29%) on December 31, 2023.
- During the last 3 years, MCRB annual EBITDA has fallen by -$14.68 million (-18.44%).
- MCRB annual EBITDA is now -3035.14% below its all-time high of -$3.01 million, reached on December 31, 2012.
Performance
MCRB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$49.63 M
-$21.63 M-77.23%
September 30, 2024
Summary
- As of February 7, 2025, MCRB quarterly EBITDA is -$49.63 million, with the most recent change of -$21.63 million (-77.23%) on September 30, 2024.
- Over the past year, MCRB quarterly EBITDA has dropped by -$103.66 million (-191.86%).
- MCRB quarterly EBITDA is now -170.44% below its all-time high of $70.45 million, reached on September 30, 2021.
Performance
MCRB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$57.52 M
-$10.30 M-21.81%
September 30, 2024
Summary
- As of February 7, 2025, MCRB TTM EBITDA is -$57.52 million, with the most recent change of -$10.30 million (-21.81%) on September 30, 2024.
- Over the past year, MCRB TTM EBITDA has dropped by -$55.65 million (-2988.94%).
- MCRB TTM EBITDA is now -279.44% below its all-time high of $32.05 million, reached on March 31, 2024.
Performance
MCRB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MCRB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +60.3% | -191.9% | -2988.9% |
| 3 y3 years | -18.4% | +24.0% | +75.8% |
| 5 y5 years | -3.5% | +24.0% | +75.8% |
MCRB EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -66.3% | +60.3% | -191.9% | +26.8% | -279.4% | +77.1% |
| 5 y | 5-year | -66.3% | +60.3% | -170.4% | +26.8% | -279.4% | +77.1% |
| alltime | all time | -3035.1% | +60.3% | -170.4% | +26.8% | -279.4% | +77.1% |
Seres Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$49.63 M(+77.2%) | -$57.52 M(+21.8%) |
| Jun 2024 | - | -$28.00 M(-17.4%) | -$47.22 M(-247.3%) |
| Mar 2024 | - | -$33.91 M(-162.8%) | $32.05 M(-1821.4%) |
| Dec 2023 | -$94.31 M(-60.3%) | $54.03 M(-237.4%) | -$1.86 M(-98.5%) |
| Sep 2023 | - | -$39.33 M(-176.7%) | -$121.18 M(-12.4%) |
| Jun 2023 | - | $51.27 M(-175.6%) | -$138.38 M(-44.9%) |
| Mar 2023 | - | -$67.83 M(+3.9%) | -$251.19 M(+5.8%) |
| Dec 2022 | -$237.51 M(+318.7%) | -$65.29 M(+15.5%) | -$237.51 M(+8.0%) |
| Sep 2022 | - | -$56.53 M(-8.2%) | -$219.93 M(+136.6%) |
| Jun 2022 | - | -$61.55 M(+13.7%) | -$92.95 M(+19.8%) |
| Mar 2022 | - | -$54.14 M(+13.5%) | -$77.57 M(+36.8%) |
| Dec 2021 | -$56.72 M(-28.8%) | -$47.71 M(-167.7%) | -$56.72 M(+126.9%) |
| Sep 2021 | - | $70.45 M(-252.6%) | -$24.99 M(-79.7%) |
| Jun 2021 | - | -$46.17 M(+38.7%) | -$123.42 M(+29.2%) |
| Mar 2021 | - | -$33.29 M(+108.3%) | -$95.56 M(+20.0%) |
| Dec 2020 | -$79.63 M(+28.1%) | -$15.98 M(-42.9%) | -$79.63 M(-0.6%) |
| Sep 2020 | - | -$27.97 M(+52.8%) | -$80.12 M(+20.2%) |
| Jun 2020 | - | -$18.30 M(+5.4%) | -$66.68 M(+16.5%) |
| Mar 2020 | - | -$17.36 M(+5.4%) | -$57.21 M(-8.0%) |
| Dec 2019 | -$62.17 M | -$16.48 M(+13.4%) | -$62.17 M(-2.9%) |
| Sep 2019 | - | -$14.53 M(+64.4%) | -$64.03 M(-8.2%) |
| Jun 2019 | - | -$8.84 M(-60.4%) | -$69.74 M(-19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$22.33 M(+21.8%) | -$87.08 M(-4.4%) |
| Dec 2018 | -$91.08 M(+10.9%) | -$18.34 M(-9.4%) | -$91.08 M(-7.6%) |
| Sep 2018 | - | -$20.24 M(-22.7%) | -$98.60 M(+17.6%) |
| Jun 2018 | - | -$26.18 M(-0.5%) | -$83.81 M(-0.6%) |
| Mar 2018 | - | -$26.32 M(+1.8%) | -$84.29 M(+2.6%) |
| Dec 2017 | -$82.12 M(-7.3%) | -$25.86 M(+374.6%) | -$82.12 M(+2.3%) |
| Sep 2017 | - | -$5.45 M(-79.6%) | -$80.24 M(-13.4%) |
| Jun 2017 | - | -$26.66 M(+10.3%) | -$92.64 M(-0.7%) |
| Mar 2017 | - | -$24.16 M(+0.8%) | -$93.25 M(+5.2%) |
| Dec 2016 | -$88.63 M(+63.7%) | -$23.98 M(+34.4%) | -$88.62 M(+4.9%) |
| Sep 2016 | - | -$17.84 M(-34.6%) | -$84.46 M(+4.5%) |
| Jun 2016 | - | -$27.27 M(+39.6%) | -$80.82 M(+22.7%) |
| Mar 2016 | - | -$19.53 M(-1.5%) | -$65.84 M(+21.6%) |
| Dec 2015 | -$54.13 M(+231.9%) | -$19.82 M(+39.5%) | -$54.13 M(+26.3%) |
| Sep 2015 | - | -$14.21 M(+15.6%) | -$42.86 M(+33.2%) |
| Jun 2015 | - | -$12.29 M(+57.3%) | -$32.19 M(+43.2%) |
| Mar 2015 | - | -$7.81 M(-8.7%) | -$22.48 M(+37.8%) |
| Dec 2014 | -$16.31 M(+173.1%) | -$8.55 M(+142.2%) | -$16.31 M(+110.3%) |
| Sep 2014 | - | -$3.53 M(+36.8%) | -$7.76 M(+83.6%) |
| Jun 2014 | - | -$2.58 M(+57.2%) | -$4.22 M(+157.2%) |
| Mar 2014 | - | -$1.64 M | -$1.64 M |
| Dec 2013 | -$5.97 M(+98.5%) | - | - |
| Dec 2012 | -$3.01 M | - | - |
FAQ
- What is Seres Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Seres Therapeutics?
- What is Seres Therapeutics annual EBITDA year-on-year change?
- What is Seres Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Seres Therapeutics?
- What is Seres Therapeutics quarterly EBITDA year-on-year change?
- What is Seres Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Seres Therapeutics?
- What is Seres Therapeutics TTM EBITDA year-on-year change?
What is Seres Therapeutics annual EBITDA?
The current annual EBITDA of MCRB is -$94.31 M
What is the all time high annual EBITDA for Seres Therapeutics?
Seres Therapeutics all-time high annual EBITDA is -$3.01 M
What is Seres Therapeutics annual EBITDA year-on-year change?
Over the past year, MCRB annual EBITDA has changed by +$143.20 M (+60.29%)
What is Seres Therapeutics quarterly EBITDA?
The current quarterly EBITDA of MCRB is -$49.63 M
What is the all time high quarterly EBITDA for Seres Therapeutics?
Seres Therapeutics all-time high quarterly EBITDA is $70.45 M
What is Seres Therapeutics quarterly EBITDA year-on-year change?
Over the past year, MCRB quarterly EBITDA has changed by -$103.66 M (-191.86%)
What is Seres Therapeutics TTM EBITDA?
The current TTM EBITDA of MCRB is -$57.52 M
What is the all time high TTM EBITDA for Seres Therapeutics?
Seres Therapeutics all-time high TTM EBITDA is $32.05 M
What is Seres Therapeutics TTM EBITDA year-on-year change?
Over the past year, MCRB TTM EBITDA has changed by -$55.65 M (-2988.94%)